Navigation Links
Precision Therapeutics Announces Two Pancreatic Cancer Studies Emphasizing the Utility of ChemoFx® in Cancer Treatment Options
Date:1/19/2011

PITTSBURGH, Jan. 19, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. will present pancreatic cancer data based on Precision's ChemoFx® in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, California.  

The two studies accepted by the ASCO GI are titled, InVitro Sensitivity of 5 FU and Gemcitabine in Pancreatic Cancer and Pattern of In Vitro Chemotherapy Response in Pancreatic Cancer and its Clinical Implication and will be presented by Drs. Jan Franko, Malcolm Bilimoria, Sricharan Chalikonda and David Iannitti.  The data demonstrate high (76%) in-vitro chemoresistance to traditional chemotherapy (gemcitabine or 5-FU as single agents); however, tumors resistant to one drug were not necessarily resistant to the other.  Moreover, 22% of the tumors found to be resistant to traditional single agent chemotherapy were observed to be sensitive to gemcitabine and 5-FU as a combination.  

"Traditionally, chemotherapy is selected based on the histology and site of tumor origin, but is not patient-specific.  The poor efficacy of this empirical approach is seen in daily clinical practice," says Dr. Jan Franko, lead investigator on the studies. "Our work supports the notion that the selection of chemotherapeutic agents may need to be based on the unique characteristics of a tumor sampled from patients.  ChemoFx® may assist with this by providing information on which drugs may actually be active in individual patients."

Pancreatic cancer kills an estimated 37,000 Americans per year and while recent studies on drug combinations have been promising, improvements in survival have been minimal over the past twenty-five years.

About Precision Therapeutics

Precision Therapeutics, a life-science company based in Pittsburgh, Pennsylvania, is committed to improving outcomes of cancer patients.  As leaders in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, Precision develops novel markers to help guide treatment decisions based on the biological processes of each individual's cancer.

Precision's state of the art bioinformatics combined with the analysis of the live molecular, proteomic and genomic activity of each patient's cancer offer an innovative foundation for further development and commercialization of novel predictive markers for cancer therapy. 

About ChemoFx®

Precision's first commercial test, ChemoFx®, is a proprietary drug response marker which measures an individual's malignant tumor response to a range of standard therapeutic alternatives under consideration by a physician. For more information, please visit www.precisiontherapeutics.com, or www.chemofx.com.


'/>"/>
SOURCE Precision Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. SACHEM Launches 2-D HPLC e-Learning Program : New e-Learning Program Teaches Scientists How to Better Analyze and Prove Product Purity Through Greater Sensitivity and Precision in Identification of Trace Components
2. Applied Precision Introduces New Super-Resolution Imaging System Doubling Resolution of Traditional Microscopes
3. Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
4. AMDL, Inc. Signs First Customer Agreement With Precision Diagnostic Laboratory for DR-70 (FDP) Cancer Test
5. Frost & Sullivan Awards Precision Biosciences for Technology Innovation and Molecular Design Process in the Genomics Market
6. NISTs LIDAR may offer peerless precision in remote measurements
7. Precision Stability Storage Announces Upcoming Expansion
8. New statistical technique improves precision of nanotechnology data
9. Precision Therapeutics Named to Inc. Magazines List of Fastest Growing Companies
10. Precision Antibody Wins Contract to Develop Gold Standard Antibodies as Part of National Cancer Institutes Clinical Proteomics Technologies for Cancer (CPTC) Initiative
11. Stretching single molecules allows precision studies of interacting electrons
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the ... the Supplyframe Design Lab . Located in Pasadena, Calif., the Design Lab’s ... how hardware projects are designed, built and brought to market. , The Design ...
(Date:6/23/2016)... ... , ... In a new case report published today in STEM CELLS Translational ... lymphedema after being treated for breast cancer benefitted from an injection of stem cells ... this debilitating, frequent side effect of cancer treatment. , Lymphedema refers to ...
(Date:6/23/2016)... 23, 2016  Blueprint Bio, a company dedicated to ... medical community, has closed its Series A funding round, ... "We have received a commitment from Forentis ... need to meet our current goals," stated Matthew ... runway to complete validation on the current projects in ...
(Date:6/23/2016)... 23, 2016 On Wednesday, June 22, ... down 0.22%; the Dow Jones Industrial Average edged 0.27% lower ... 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following ... Therapeutics (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
Breaking Biology News(10 mins):